Percutaneous treatment of peripheral vascular disease: The role of diabetes and inflammation

Journal of Vascular Surgery

Volumn 45, Issue 6 SUPPL., 2007, Pages A149-A157

  Nguyen, Louis L ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PENTOXIFYLLINE;

ANGIOPLASTY; ARTICLE; BLOOD VESSEL CATHETERIZATION; CARDIOVASCULAR RISK; COST EFFECTIVENESS ANALYSIS; DIABETES MELLITUS; DYSLIPIDEMIA; HEMODYNAMICS; HUMAN; HYPERTENSION; INFLAMMATION; INSULIN RESISTANCE; INTERMITTENT CLAUDICATION; INTERVENTIONAL CARDIOVASCULAR PROCEDURE; OUTCOME ASSESSMENT; PERCUTANEOUS PERIPHERAL INTERVENTION; PERIPHERAL VASCULAR DISEASE; PRIORITY JOURNAL; QUALITY ADJUSTED LIFE YEAR; RISK FACTOR; STENT; TREATMENT OUTCOME;

EID: 34249297404     PISSN: 07415214     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jvs.2007.02.029     Document Type: Article

References (109)

1. Creager M.A. Medical management of peripheral arterial disease. Cardiol Rev 9 (2001) 238-245
2. Management of peripheral arterial disease (PAD). TransAtlantic Inter-Society Consensus (TASC). Eur J Vasc Endovasc Surg 19 suppl A (2000) Si-xxviii, S1-250
3. Amighi J., Sabeti S., Schlager O., Francesconi M., Ahmadi R., Minar E., et al. Outcome of conservative therapy of patients with severe intermittent claudication. Eur J Vasc Endovasc Surg 27 (2004) 254-258
4. Beebe H.G. Intermittent claudication: effective medical management of a common circulatory problem. Am J Cardiol 87 (2001) 14D-18D
5. Lindgarde F., Jelnes R., Bjorkman H., Adielsson G., Kjellstrom T., Palmquist I., et al., Scandinavian Study Group. Conservative drug treatment in patients with moderately severe chronic occlusive peripheral arterial disease. Circulation 80 (1989) 1549-1556
6. Money S.R., Herd J.A., Isaacsohn J.L., Davidson M., Cutler B., Heckman J., et al. Effect of cilostazol on walking distances in patients with intermittent claudication caused by peripheral vascular disease. J Vasc Surg 27 (1998) 267-274 discussion 274-5
7. Comerota A.J. Endovascular and surgical revascularization for patients with intermittent claudication. Am J Cardiol 87 (2001) 34D-43D
8. Smith F.B., Lee A.J., Price J.F., van Wijk M.C., and Fowkes F.G. Changes in ankle brachial index in symptomatic and asymptomatic subjects in the general population. J Vasc Surg 38 (2003) 1323-1330
9. Dormandy J., Heeck L., and Vig S. The natural history of claudication: risk to life and limb. Semin Vasc Surg 12 (1999) 123-137
10. Gardner A.W., Montgomery P.S., and Killewich L.A. Natural history of physical function in older men with intermittent claudication. J Vasc Surg 40 (2004) 73-78
11. Brevetti G., and Chiariello M. Peripheral arterial disease: the magnitude of the problem and its socioeconomic impact. Curr Drug Targets Cardiovasc Haematol Disord 4 (2004) 199-208
12. Ambrosetti M., Salerno M., Boni S., Daniele G., Tramarin R., and Pedretti R.F. Economic evaluation of a short-course intensive rehabilitation program in patients with intermittent claudication. Int Angiol 23 (2004) 108-113
13. Gardner A.W., Katzel L.I., Sorkin J.D., Bradham D.D., Hochberg M.C., Flinn W.R., et al. Exercise rehabilitation improves functional outcomes and peripheral circulation in patients with intermittent claudication: a randomized controlled trial. J Am Geriatr Soc 49 (2001) 755-762
14. Barker G.A., Green S., and Walker P.J. Effect of carbohydrate supplementation on walking performance in peripheral arterial disease: a preliminary physiologic study. J Vasc Surg 40 (2004) 932-938
15. Bylund A.C., Hammarsten J., Holm J., and Schersten T. Enzyme activities in skeletal muscles from patients with peripheral arterial insufficiency. Eur J Clin Invest 6 (1976) 425-429
16. de Vries S.O., Donaldson M.C., and Hunink M.G. Contralateral symptoms after unilateral intervention for peripheral occlusive disease. J Vasc Surg 27 (1998) 414-421
17. Muluk S.C., Muluk V.S., Kelley M.E., Whittle J.C., Tierney J.A., Webster M.W., et al. Outcome events in patients with claudication: a 15-year study in 2777 patients. J Vasc Surg 33 (2001) 251-257 discussion 257-8
18. Zimmet P., Alberti K.G., and Shaw J. Global and societal implications of the diabetes epidemic. Nature 414 (2001) 782-787
19. Gregg E.W., Beckles G.L., Williamson D.F., Leveille S.G., Langlois J.A., Engelgau M.M., et al. Diabetes and physical disability among older U.S. adults. Diabetes Care 23 (2000) 1272-1277
20. Al-Delaimy W.K., Merchant A.T., Rimm E.B., Willett W.C., Stampfer M.J., and Hu F.B. Effect of type 2 diabetes and its duration on the risk of peripheral arterial disease among men. Am J Med 116 (2004) 236-240
21. Dolan N.C., Liu K., Criqui M.H., Greenland P., Guralnik J.M., Chan C., et al. Peripheral artery disease, diabetes, and reduced lower extremity functioning. Diabetes Care 25 (2002) 113-120
22. Ford E.S., Giles W.H., and Dietz W.H. Prevalence of the metabolic syndrome among US adults: findings from the third National Health and Nutrition Examination Survey. JAMA 287 (2002) 356-359
23. Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP). JAMA 285 (2001) 2486-2497
24. Park L., Raman K.G., Lee K.J., Lu Y., Ferran Jr. L.J., Chow W.S., et al. Suppression of accelerated diabetic atherosclerosis by the soluble receptor for advanced glycation endproducts. Nat Med 4 (1998) 1025-1031
25. Falcone C., Emanuele E., D'Angelo A., Buzzi M.P., Belvito C., Cuccia M., et al. Plasma levels of soluble receptor for advanced glycation end products and coronary artery disease in nondiabetic men. Arterioscler Thromb Vasc Biol 25 (2005) 1032-1037
26. Aquino R., Johnnides C., Makaroun M., Whittle J.C., Muluk V.S., Kelley M.E., et al. Natural history of claudication: long-term serial follow-up study of 1244 claudicants. J Vasc Surg 34 (2001) 962-970
27. Jonason T., and Ringqvist I. Diabetes mellitus and intermittent claudication. Relation between peripheral vascular complications and location of the occlusive atherosclerosis in the legs. Acta Med Scand 218 (1985) 217-221
28. McDaniel M.D., and Cronenwett J.L. Basic data related to the natural history of intermittent claudication. Ann Vasc Surg 3 (1989) 273-277
29. Lange S., Diehm C., Darius H., Haberl R., Allenberg J.R., Pittrow D., et al. High prevalence of peripheral arterial disease and low treatment rates in elderly primary care patients with diabetes. Exp Clin Endocrinol Diabetes 112 (2004) 566-573
30. Matzke S., and Lepantalo M. Claudication does not always precede critical leg ischemia. Vasc Med 6 (2001) 77-80
31. Isomaa B., Almgren P., Tuomi T., Forsen B., Lahti K., Nissen M., et al. Cardiovascular morbidity and mortality associated with the metabolic syndrome. Diabetes Care 24 (2001) 683-689
32. Yip J., Facchini F.S., and Reaven G.M. Resistance to insulin-mediated glucose disposal as a predictor of cardiovascular disease. J Clin Endocrinol Metab 83 (1998) 2773-2776
33. Ridker P.M., Rifai N., Stampfer M.J., and Hennekens C.H. Plasma concentration of interleukin-6 and the risk of future myocardial infarction among apparently healthy men. Circulation 101 (2000) 1767-1772
34. Ridker P.M., Rifai N., Pfeffer M., Sacks F., Lepage S., and Braunwald E. Elevation of tumor necrosis factor-alpha and increased risk of recurrent coronary events after myocardial infarction. Circulation 101 (2000) 2149-2153
35. Ridker P.M., Buring J.E., and Rifai N. Soluble P-selectin and the risk of future cardiovascular events. Circulation 103 (2001) 491-495
36. Hwang S.J., Ballantyne C.M., Sharrett A.R., Smith L.C., Davis C.E., Gotto Jr. A.M., et al. Circulating adhesion molecules VCAM-1, ICAM-1, and E-selectin in carotid atherosclerosis and incident coronary heart disease cases: the Atherosclerosis Risk In Communities (ARIC) study. Circulation 96 (1997) 4219-4225
37. Vishnevetsky D., Kiyanista V.A., and Gandhi P.J. CD40 ligand: a novel target in the fight against cardiovascular disease. Ann Pharmacother 38 (2004) 1500-1508
38. Lim H.S., Blann A.D., and Lip G.Y. Soluble CD40 ligand, soluble P-selectin, interleukin-6, and tissue factor in diabetes mellitus: relationships to cardiovascular disease and risk factor intervention. Circulation 109 (2004) 2524-2528
39. Jinchuan Y., Zonggui W., Jinming C., Li L., and Xiantao K. Upregulation of CD40-CD40 ligand system in patients with diabetes mellitus. Clin Chim Acta 339 (2004) 85-90
40. Cipollone F., Chiarelli F., Davi G., Ferri C., Desideri G., Fazia M., et al. Enhanced soluble CD40 ligand contributes to endothelial cell dysfunction in vitro and monocyte activation in patients with diabetes mellitus: effect of improved metabolic control (2005), Diabetologia
41. Zwaka T.P., Hombach V., and Torzewski J. C-reactive protein-mediated low density lipoprotein uptake by macrophages: implications for atherosclerosis. Circulation 103 (2001) 1194-1197
42. Schillinger M., Exner M., Mlekusch W., Sabeti S., Amighi J., Nikowitsch R., et al. Inflammation and Carotid Artery--Risk for Atherosclerosis Study (ICARAS). Circulation 111 (2005) 2203-2209
43. van der Meer I.M., de Maat M.P., Bots M.L., Breteler M.M., Meijer J., Kiliaan A.J., et al. Inflammatory mediators and cell adhesion molecules as indicators of severity of atherosclerosis: the Rotterdam Study. Arterioscler Thromb Vasc Biol 22 (2002) 838-842
44. Cassar K., Bachoo P., Ford I., Greaves M., and Brittenden J. Markers of coagulation activation, endothelial stimulation and inflammation in patients with peripheral arterial disease. Eur J Vasc Endovasc Surg 29 (2005) 171-176
45. McDermott M.M., Guralnik J.M., Greenland P., Green D., Liu K., Ridker P.M., et al. Inflammatory and thrombotic blood markers and walking-related disability in men and women with and without peripheral arterial disease. J Am Geriatr Soc 52 (2004) 1888-1894
46. Engstrom G., Site-Flondell D., Lindblad B., Janzon L., and Lindgarde F. Risk of treatment of peripheral arterial disease is related to inflammation-sensitive plasma proteins: a prospective cohort study. J Vasc Surg 40 (2004) 1101-1105
47. Brevetti G., Silvestro A., Di Giacomo S., Bucur R., Di Donato A., Schiano V., et al. Endothelial dysfunction in peripheral arterial disease is related to increase in plasma markers of inflammation and severity of peripheral circulatory impairment but not to classic risk factors and atherosclerotic burden. J Vasc Surg 38 (2003) 374-379
48. Verma S., Kuliszewski M.A., Li S.H., Szmitko P.E., Zucco L., Wang C.H., et al. C-reactive protein attenuates endothelial progenitor cell survival, differentiation, and function: further evidence of a mechanistic link between C-reactive protein and cardiovascular disease. Circulation 109 (2004) 2058-2067
49. Fernandez-Real J.M., Vayreda M., Richart C., Gutierrez C., Broch M., Vendrell J., et al. Circulating interleukin 6 levels, blood pressure, and insulin sensitivity in apparently healthy men and women. J Clin Endocrinol Metab 86 (2001) 1154-1159
50. Mohamed-Ali V., Goodrick S., Rawesh A., Katz D.R., Miles J.M., Yudkin J.S., et al. Subcutaneous adipose tissue releases interleukin-6, but not tumor necrosis factor-alpha, in vivo. J Clin Endocrinol Metab 82 (1997) 4196-4200
51. Ikeda U., Ohkawa F., Seino Y., Yamamoto K., Hidaka Y., Kasahara T., et al. Serum interleukin 6 levels become elevated in acute myocardial infarction. J Mol Cell Cardiol 24 (1992) 579-584
52. Harris T.B., Ferrucci L., Tracy R.P., Corti M.C., Wacholder S., Ettinger Jr. W.H., et al. Associations of elevated interleukin-6 and C-reactive protein levels with mortality in the elderly. Am J Med 106 (1999) 506-512
53. Speidl W.S., Zeiner A., Nikfardjam M., Geppert A., Jordanova N., Niessner A., et al. An increase of C-reactive protein is associated with enhanced activation of endogenous fibrinolysis at baseline but an impaired endothelial fibrinolytic response after venous occlusion. J Am Coll Cardiol 45 (2005) 30-34
54. Wilhelmsen L., Svardsudd K., Korsan-Bengtsen K., Larsson B., Welin L., and Tibblin G. Fibrinogen as a risk factor for stroke and myocardial infarction. N Engl J Med 311 (1984) 501-505
55. Juhan-Vague I., Pyke S.D., Alessi M.C., Jespersen J., Haverkate F., and Thompson S.G. Fibrinolytic factors and the risk of myocardial infarction or sudden death in patients with angina pectoris. ECAT Study Group. European Concerted Action on Thrombosis and Disabilities. Circulation 94 (1996) 2057-2063
56. Lindgren A., Lindoff C., Norrving B., Astedt B., and Johansson B.B. Tissue plasminogen activator and plasminogen activator inhibitor-1 in stroke patients. Stroke 27 (1996) 1066-1071
57. Koksch M., Zeiger F., Wittig K., Siegemund A., Reininger C.B., Pfeiffer D., et al. Coagulation, fibrinolysis and platelet P-selectin expression in peripheral vascular disease. Eur J Vasc Endovasc Surg 21 (2001) 147-154
58. Killewich L.A., Gardner A.W., Macko R.F., Hanna D.J., Goldberg A.P., Cox D.K., et al. Progressive intermittent claudication is associated with impaired fibrinolysis. J Vasc Surg 27 (1998) 645-650
59. Killewich L.A., Macko R.F., Montgomery P.S., Wiley L.A., and Gardner A.W. Exercise training enhances endogenous fibrinolysis in peripheral arterial disease. J Vasc Surg 40 (2004) 741-745
60. Di Benedetto A., Russo G.T., Corrado F., Di Cesare E., Alessi E., Nicocia G., et al. Inflammatory markers in women with a recent history of gestational diabetes mellitus. J Endocrinol Invest 28 (2005) 34-38
61. Fernandez-Real J.M., and Ricart W. Insulin resistance and chronic cardiovascular inflammatory syndrome. Endocr Rev 24 (2003) 278-301
62. Dandona P., Aljada A., Chaudhuri A., Mohanty P., and Garg R. Metabolic syndrome: a comprehensive perspective based on interactions between obesity, diabetes, and inflammation. Circulation 111 (2005) 1448-1454
63. Mohanty P., Aljada A., Ghanim H., Hofmeyer D., Tripathy D., Syed T., et al. Evidence for a potent antiinflammatory effect of rosiglitazone. J Clin Endocrinol Metab 89 (2004) 2728-2735
64. Schillinger M., Exner M., Amighi J., Mlekusch W., Sabeti S., Rumpold H., et al. Joint effects of C-reactive protein and glycated hemoglobin in predicting future cardiovascular events of patients with advanced atherosclerosis. Circulation 108 (2003) 2323-2328
65. Cheng S.W., Ting A.C., and Wong J. Endovascular stenting of superficial femoral artery stenosis and occlusions: results and risk factor analysis. Cardiovasc Surg 9 (2001) 133-140
66. Gordon I.L., Conroy R.M., Arefi M., Tobis J.M., Stemmer E.A., and Wilson S.E. Three-year outcome of endovascular treatment of superficial femoral artery occlusion. Arch Surg 136 (2001) 221-228
67. Pozzi Mucelli F., Fisicaro M., Calderan L., Malacrea M., Mazzone C., Cattin L., et al. Percutaneous revascularization of femoropopliteal artery disease: PTA and PTA plus stent. Results after six years' follow-up. Radiol Med (Torino) 105 (2003) 339-349
68. Duda S.H., Bosiers M., Lammer J., Scheinert D., Zeller T., Tielbeek A., et al. Sirolimus-Eluting versus Bare Nitinol Stent for Obstructive Superficial Femoral Artery Disease: The SIROCCO II Trial. J Vasc Interv Radiol 16 (2005) 331-338
69. Surowiec S.M., Davies M.G., Eberly S.W., Rhodes J.M., Illig K.A., Shortell C.K., et al. Percutaneous angioplasty and stenting of the superficial femoral artery. J Vasc Surg 41 (2005) 269-278
70. Cheng S.W., Ting A.C., and Ho P. Angioplasty and primary stenting of high-grade, long-segment superficial femoral artery disease: is it worthwhile?. Ann Vasc Surg 17 (2003) 430-437
71. Jamsen T.S., Manninen H.I., Tulla H.E., Jaakkola P.A., and Matsi P.J. Infrainguinal revascularization because of claudication: total long-term outcome of endovascular and surgical treatment. J Vasc Surg 37 (2003) 808-815
72. Lasic Z., Nikolsky E., Kesanakurthy S., and Dangas G. Vascular closure devices: a review of their use after invasive procedures. Am J Cardiovasc Drugs 5 (2005) 185-200
73. Liistro F., Falsini G., and Bolognese L. The clinical burden of contrast media-induced nephropathy. Ital Heart J 4 (2003) 668-676
74. Costanza M.J., Queral L.A., Lilly M.P., and Finn W.R. Hemodynamic outcome of endovascular therapy for TransAtlantic InterSociety Consensus type B femoropopliteal arterial occlusive lesions. J Vasc Surg 39 (2004) 343-350
75. Sabeti S., Mlekusch W., Amighi J., Minar E., and Schillinger M. Primary patency of long-segment self-expanding nitinol stents in the femoropopliteal arteries. J Endovasc Ther 12 (2005) 6-12
76. Maca T., Schillinger M., Hamwi A., Mlekusch W., Sabeti S., Wagner O., et al. Insulin, C-peptide, and restenosis after femoral artery balloon angioplasty in type II diabetic and nondiabetic patients. J Vasc Interv Radiol 16 (2005) 31-35
77. Mehran R., Dangas G.D., Kobayashi Y., Lansky A.J., Mintz G.S., Aymong E.D., et al. Short- and long-term results after multivessel stenting in diabetic patients. J Am Coll Cardiol 43 (2004) 1348-1354
78. Gilbert J., Raboud J., and Zinman B. Meta-analysis of the effect of diabetes on restenosis rates among patients receiving coronary angioplasty stenting. Diabetes Care 27 (2004) 990-994
79. Choi D., Kim S.K., Choi S.H., Ko Y.G., Ahn C.W., Jang Y., et al. Preventative effects of rosiglitazone on restenosis after coronary stent implantation in patients with type 2 diabetes. Diabetes Care 27 (2004) 2654-2660
80. Versaci F., and Gaspardone A. Prevention of restenosis after stenting: the emerging role of inflammation. Coron Artery Dis 15 (2004) 307-311
81. Li J.J., Fang C.H., Jiang H., Huang C.X., Hui R.T., and Chen M.Z. Time course of inflammatory response after renal artery stenting in patients with atherosclerotic renal stenosis. Clin Chim Acta 350 (2004) 115-121
82. Aggarwal A., Schneider D.J., Sobel B.E., and Dauerman H.L. Comparison of inflammatory markers in patients with diabetes mellitus versus those without before and after coronary arterial stenting. Am J Cardiol 92 (2003) 924-929
83. Danielsson P., Danielsson G., Truedsson L., and Norgren L. White blood cell and endothelial cell response to endovascular procedures in the leg. Int Angiol 23 (2004) 122-127
84. Manfredini F., Conconi F., Malagoni A.M., Manfredini R., Mascoli F., Liboni A., et al. Speed rather than distance: a novel graded treadmill test to assess claudication. Eur J Vasc Endovasc Surg 28 (2004) 303-309
85. Gelin J., Jivegard L., Taft C., Karlsson J., Sullivan M., Dahllof A.G., et al. Treatment efficacy of intermittent claudication by surgical intervention, supervised physical exercise training compared to no treatment in unselected randomised patients I: one year results of functional and physiological improvements. Eur J Vasc Endovasc Surg 22 (2001) 107-113
86. Khaira H.S., Hanger R., and Shearman C.P. Quality of life in patients with intermittent claudication. Eur J Vasc Endovasc Surg 11 (1996) 65-69
87. Hiatt W.R., Hirsch A.T., Regensteiner J.G., Brass E.P., and Vascular Clinical Trialists. Clinical trials for claudication. Assessment of exercise performance, functional status, and clinical end points. Circulation 92 (1995) 614-621
88. McDermott M.M., Liu K., Guralnik J.M., Martin G.J., Criqui M.H., and Greenland P. Measurement of walking endurance and walking velocity with questionnaire: validation of the walking impairment questionnaire in men and women with peripheral arterial disease. J Vasc Surg 28 (1998) 1072-1081
89. de Vries S.O., Kuipers W.D., and Hunink M.G. Intermittent claudication: symptom severity versus health values. J Vasc Surg 27 (1998) 422-430
90. Johnson J.A., Luo N., Shaw J.W., Kind P., and Coons S.J. Valuations of EQ-5D health states: are the United States and United Kingdom different?. Med Care 43 (2005) 221-228
91. Kulkarni A.S., Balkrishnan R., Richmond D., Pearce D.J., and Feldman S.R. Medication-related factors affecting health care outcomes and costs for patients with psoriasis in the United States. J Am Acad Dermatol 52 (2005) 27-31
92. Wolfe F., and Michaud K. Severe rheumatoid arthritis (RA), worse outcomes, comorbid illness, and sociodemographic disadvantage characterize RA patients with fibromyalgia. J Rheumatol 31 (2004) 695-700
93. Bosch J.L., and Hunink M.G. Comparison of the Health Utilities Index Mark 3 (HUI3) and the EuroQol EQ-5D in patients treated for intermittent claudication. Qual Life Res 9 (2000) 591-601
94. Bosch J.L., van der Graaf Y., Hunink M.G., and The Dutch Iliac Stent Trial Study Group. Health-related quality of life after angioplasty and stent placement in patients with iliac artery occlusive disease: results of a randomized controlled clinical trial. Circulation 99 (1999) 3155-3160
95. Menard J.R., Smith H.E., Riebe D., Braun C.M., Blissmer B., and Patterson R.B. Long-term results of peripheral arterial disease rehabilitation. J Vasc Surg 39 (2004) 1186-1192
96. Nehler M.R., McDermott M.M., Treat-Jacobson D., Chetter I., and Regensteiner J.G. Functional outcomes and quality of life in peripheral arterial disease: current status. Vasc Med 8 (2003) 115-126
97. Long J., Modrall J.G., Parker B.J., Swann A., Welborn III M.B., and Anthony T. Correlation between ankle-brachial index, symptoms, and health-related quality of life in patients with peripheral vascular disease. J Vasc Surg 39 (2004) 723-727
98. Currie I.C., Wilson Y.G., Baird R.N., and Lamont P.M. Treatment of intermittent claudication: the impact on quality of life. Eur J Vasc Endovasc Surg 10 (1995) 356-361
99. McDermott M.M., Liu K., Greenland P., Guralnik J.M., Criqui M.H., Chan C., et al. Functional decline in peripheral arterial disease: associations with the ankle brachial index and leg symptoms. JAMA 292 (2004) 453-461
100. Pell J.P., and The Scottish Vascular Audit Group. Impact of intermittent claudication on quality of life. Eur J Vasc Endovasc Surg 9 (1995) 469-472
101. de Vries S.O., Visser K., de Vries J.A., Wong J.B., Donaldson M.C., and Hunink M.G. Intermittent claudication: cost-effectiveness of revascularization versus exercise therapy. Radiology 222 (2002) 25-36
102. Treesak C., Kasemsup V., Treat-Jacobson D., Nyman J.A., and Hirsch A.T. Cost-effectiveness of exercise training to improve claudication symptoms in patients with peripheral arterial disease. Vasc Med 9 (2004) 279-285
103. Bosch J.L., Haaring C., Meyerovitz M.F., Cullen K.A., and Hunink M.G. Cost-effectiveness of percutaneous treatment of iliac artery occlusive disease in the United States. AJR Am J Roentgenol 175 (2000) 517-521
104. Bosch J.L., Tetteroo E., Mali W.P., Hunink M.G., and Dutch Iliac Stent Trial Study Group. Iliac arterial occlusive disease: cost-effectiveness analysis of stent placement versus percutaneous transluminal angioplasty. Radiology 208 (1998) 641-648
105. Greenberg D., Rosenfield K., Garcia L.A., Berezin R.H., Lavelle T., Fogleman S., et al. In-hospital costs of self-expanding nitinol stent implantation versus balloon angioplasty in the femoropopliteal artery (the VascuCoil Trial). J Vasc Interv Radiol 15 (2004) 1065-1069
106. Visser K., de Vries S.O., Kitslaar P.J., van Engelshoven J.M., and Hunink M.G. Cost-effectiveness of diagnostic imaging work-up and treatment for patients with intermittent claudication in The Netherlands. Eur J Vasc Endovasc Surg 25 (2003) 213-223
107. Hunink M.G., Wong J.B., Donaldson M.C., Meyerovitz M.F., de Vries J., and Harrington D.P. Revascularization for femoropopliteal disease. A decision and cost-effectiveness analysis. JAMA 274 (1995) 165-171
108. Jansen R.M., de Vries S.O., Cullen K.A., Donaldson M.C., and Hunink M.G. Cost-identification analysis of revascularization procedures on patients with peripheral arterial occlusive disease. J Vasc Surg 28 (1998) 617-623
109. Silber J.H., Rosenbaum P.R., Trudeau M.E., Chen W., Zhang X., Kelz R.R., et al. Changes in prognosis after the first postoperative complication. Med Care 43 (2005) 122-131